Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published online ahead of print, 2021 Feb 4]. CA Cancer J Clin. 2021 ;0:1-41.
   PubMed Web of Science ®Google Scholar
• Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013;2(1):3.
   PubMedGoogle Scholar
• Li LQ, Pan D, Zhang SW, et al. autophagy regulates chemoresistance of gastric cancer stem cells via the Notch signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(11):3402–3407.
   PubMed Web of Science ®Google Scholar
• Rashidi MR, Mehta P, Bregenzer M, et al. Engineered 3D model of cancer stem cell enrichment and chemoresistance. Neoplasia. 2019;21(8):822–836.
   PubMed Web of Science ®Google Scholar
• Siddique HR, Saleem M. Role of BMI1, a stem-cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidence. Stem Cells. 2012;30(3):372–378.
   PubMed Web of Science ®Google Scholar
• Lee HY, Hong IS. Targeting liver cancer stem cells: an alternative therapeutic approach for liver cancer. Cancers (Basel). 2020;12(10):2746.
   Web of Science ®Google Scholar
• Mondal S, Bhattacharya K, Mandal C. Nutritional stress reprograms dedifferention in glioblastoma multiforme driven by PTEN/Wnt/Hedgehog axis: a stochastic model of cancer stem cells. Cell Death Discov. 2018;4(1):110.
   PubMedGoogle Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676. .
   PubMed Web of Science ®Google Scholar
• Huang J, Chen T, Liu X, et al. More synergetic cooperation of Yamanaka factors in induced pluripotent stem cells than in embryonic stem cells. Cell Res. 2009;19(10):1127–1138.
   PubMed Web of Science ®Google Scholar
• Holczbauer Á, Factor VM, Andersen JB, et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology. 2013;145(1):221–231.
   PubMed Web of Science ®Google Scholar
• Fiorenza MT, Rava A. The TCL1 function revisited focusing on metabolic requirements of stemness. Cell Cycle. 2019;18(22):3055–3063.
   PubMed Web of Science ®Google Scholar
• Roy S, Kar M, Roy S, et al. KLF4 expression in the surgical cut margin is associated with disease relapse of oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128(2):154–165.
   PubMed Web of Science ®Google Scholar
• Kiecker C, Bates T, Bell E. Molecular specification of germ layers in vertebrate embryos. Cell Mol Life Sci. 2016;73(5):923–947.
   PubMed Web of Science ®Google Scholar
• Kuo KK, Lee KT, Chen KK, et al. Positive feedback loop of OCT4 and c‐JUN expedites cancer stemness in liver cancer. Stem Cells. 2016;34(11):2613–2624.
   PubMed Web of Science ®Google Scholar
• Nio K, Yamashita T, Kaneko S. The evolving concept of liver cancer stem cells. Mol Cancer. 2017;16(1):4.
   PubMedGoogle Scholar
• Islam F, Qiao B, Smith RA, et al. Cancer stem cell: fundamental experimental pathological concepts and updates. Exp Mol Pathol. 2015;98(2):184–191.
   PubMed Web of Science ®Google Scholar
• Virchow R. Cellular pathology as based on physiological and pathological histology. Philadelphia: J B Lippincott; 1963. DOI:10.5962/bhl.title.32770.
   Google Scholar
• Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–1134. .
   PubMed Web of Science ®Google Scholar
• Siddique HR, Feldman DE, Chen CL, et al. NUMB phosphorylation destabilizes p53 and promotes self‐renewal of tumor‐initiating cells by a NANOG‐dependent mechanism in liver cancer. Hepatology. 2015;62(5):1466–1479. .
   PubMed Web of Science ®Google Scholar
• Maurya SK, Shadab G, Siddique HR. Chemosensitization of therapy resistant tumors: targeting multiple cell signaling pathways by lupeol, a pentacyclic triterpene. Curr Pharm Des. 2020;26(4):455–465.
   PubMed Web of Science ®Google Scholar
• Fatma H, Siddique HR. Role of long non-coding RNAs and MYC interaction in cancer metastasis: a possible target for therapeutic intervention. Toxicol Appl Pharmacol. 2020;399:115056.
   PubMed Web of Science ®Google Scholar
• Kim WT, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017;50(6):285–298.
   PubMed Web of Science ®Google Scholar
• Mladinich M, Ruan D, Chan CH. Tackling cancer stem cells via inhibition of EMT transcription factors. Stem Cells Int. 2016;2016:5285892.
   PubMed Web of Science ®Google Scholar
• Sławek S, Szmyt K, Fularz M, et al. Pluripotency transcription factors in lung cancer-a review. Tumour Biol. 2016;37(4):4241–4249.
   PubMedGoogle Scholar
• Padua D, Figueria P, Riberio I, et al. The relevance of transcription factors in gastric and colorectal cancer stem cells identification and eradication. Front Cell Dev Biol. 2020;8. DOI:10.3389/fcell.2020.00442.
   PubMed Web of Science ®Google Scholar
• Qiu L, Li H, Fu S, et al. Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC. Oncol Lett. 2018;15(2):2039–2048.
   PubMed Web of Science ®Google Scholar
• Siddique H, Narayan P, Punj V, et al. MSI2 binds LncRNAs and promotes self-renewal and oncogenesis through MYC expression. [abstract]. In: Proceedings of the American association for cancer research annual meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017; 77(13Suppl): doi:10.1158/1538-7445.AM2017-2542.
   Google Scholar
• Huch M, Dollé L. The plastic cellular states of liver cells: are EpCAM and Lgr5 fit for purpose? Hepatology. 2016;64(2):652–662.
   PubMed Web of Science ®Google Scholar
• Haraguchi N, Ishii H, Mimori K, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120(9):3326–3339.
   PubMed Web of Science ®Google Scholar
• Chen BD, Hui YF, Zhang HB, et al. Expression of CD90/EpCAM/CD24 in hepatocellular carcinoma cell lines at various stages of differentiation. Zhonghua Gan Zang Bing Za Zhi. 2013;21(9):688–691.
   PubMedGoogle Scholar
• Huch M, Dorrell C, Boj SF, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature. 2013;494(7436):247–250.
   PubMed Web of Science ®Google Scholar
• Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13(2):153–166.
   PubMed Web of Science ®Google Scholar
• Ma S, Lee TK, Zheng BJ, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27(12):1749–1758.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010;126(9):2067–2078.
   PubMed Web of Science ®Google Scholar
• Ma S, Chan KW, Lee TK, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res. 2008;6(7):1146–1153.
   PubMed Web of Science ®Google Scholar
• Huang J, Zhang X, Zhang M, et al. Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma. Carcinogenesis. 2006;28(5):1094–1103.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Lin M, Jiang X, et al. The recent advances on liver cancer stem cells: biomarkers, separation, and therapy. Anal Cell Pathol (Amst). 2017;2017:5108653.
   PubMedGoogle Scholar
• Fu X, Zhu X, Qin F, et al. Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner. Mol Cancer. 2018;17(1):73.
   PubMedGoogle Scholar
• Qiu Q, Hernandez JC, Dean AM, et al. CD24-positive cells from normal adult mouse liver are hepatocyte progenitor cells. Stem Cells Dev. 2011;20(12):2177–2188.
   PubMed Web of Science ®Google Scholar
• Kim H, Choi GH, Na DC, et al. Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011;54(5):1707–1717.
   PubMed Web of Science ®Google Scholar
• Lee TK, Cheung VC, Lu P, et al. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60(1):179–191.
   PubMed Web of Science ®Google Scholar
• Zhao W, Wang L, Han H, et al. 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit. Cancer Cell. 2013;23(4):541–556.
   PubMed Web of Science ®Google Scholar
• Liu S, Li N, Yu X, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology. 2013;144(5):1031–41.e10.
   PubMed Web of Science ®Google Scholar
• Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132(7):2542–2556.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest. 2013;123(5):1911–1918.
   PubMed Web of Science ®Google Scholar
• Xiang D, Cheng Z, Liu H, et al. Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients. Hepatology. 2017;65(5):1566–1580.
   PubMed Web of Science ®Google Scholar
• Lou W, Liu J, Gao Y, et al. MicroRNA regulation of liver cancer stem cells. Am J Cancer Res. 2018;8(7):1126–1141.
   PubMed Web of Science ®Google Scholar
• Afify SM, Sanchez Calle A, Hassan G, et al. A novel model of liver cancer stem cells developed from induced pluripotent stem cells. Br J Cancer. 2020;122(9):1378–1390.
   PubMed Web of Science ®Google Scholar
• Liu Q, Chen K, Liu Z, et al. BORIS upregulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells. Cancer Lett. 2017;403:165–174.
   PubMed Web of Science ®Google Scholar
• Liu Z, Dai X, Wang T, et al. Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells. Cancer Lett. 2017;400:149–160.
   PubMed Web of Science ®Google Scholar
• Lo RO, Mazza T, Giallongo S, et al. Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4+CD25+FoxP3+ regulatory T cells activation. Theranostics. 2020;10(2):910–924.
   PubMed Web of Science ®Google Scholar
• Liu D, Li H, Dong H, et al. In-situ multiomics analysis reveals only minor genetic and epigenetic changes in human liver cancer stem cells. 2021;Res square. DOI:10.21203/rs.3.rs-244209/v1
   Google Scholar
• Lo Re O, Douet J, Bushbeck M, et al. Histone variant macroH2A1 rewires carbohydrate and lipid metabolism of hepatocellular carcinoma cells towards cancer stem cells. Epigenetics. 2018;13(8):829–845.
   PubMed Web of Science ®Google Scholar
• Zhao H, Yao P, Fu N, et al. deSUMOylation signaling: a novel mechanism of liver CSC properties and hepatocarcinogenesis in hypoxia. Acta Biochim Biophys Sin (Shanghai). 2017;49(12):1135–1137.
   PubMed Web of Science ®Google Scholar
• Chang HL, Bamodu OA, Ong JR, et al. Targeting the epigenetic non-coding RNA MALAT1/Wnt signaling axis as a therapeutic approach to suppress stemness and metastasis in hepatocellular carcinoma. Cells. 2020;9(4):1020.
   Web of Science ®Google Scholar
• Zhao J, Fu Y, Wu J, et al. The diverse mechanisms of miRNAs and lncRNAs in the maintenance of liver cancer stem cells. Biomed Res Int. 2018;2018:8686027.
   PubMed Web of Science ®Google Scholar
• Chen C, Luo F, Yang Q, et al. NF-κB-regulated miR-155, via repression of QKI, contributes to the acquisition of CSC-like phenotype during the neoplastic transformation of hepatic cells induced by arsenite. Mol Carcinog. 2018;57(4):483–493.
   PubMed Web of Science ®Google Scholar
• Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8.
   PubMed Web of Science ®Google Scholar
• Malik N, Rao MS. A review of the methods for human iPSC derivation. Methods Mol Biol. 2013;997:23–33.
   PubMedGoogle Scholar
• Fatma H, Maurya SK, Siddique HR. Epigenetic modifications of c-MYC: role in cancer cell reprogramming, progression and chemoresistance [published online ahead of print, 2020 Nov 18]. Semin Cancer Biol. 2020;S1044-579X(20):30242–X.
   Google Scholar
• Li R, Liang J, Ni S, et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell. 2010;7(1):51–63.
   PubMed Web of Science ®Google Scholar
• Lagadec C, Vlashi E, Della DL, et al. Radiation-induced reprogramming of breast cancer cells. Stem Cells. 2012;30(5):833–844.
   PubMed Web of Science ®Google Scholar
• Yu F, Li J, Chen H, et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene. 2011;30(18):2161–2172.
   PubMed Web of Science ®Google Scholar
• Wolfer A, Wittner BS, Irimia D, et al. MYC regulation of a “poor-prognosis” metastatic cancer cell state. Proc Natl Acad Sci U S A. 2010;107(8):3698–3703.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang H, Li Z, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One. 2008;3(11):e3769.
   PubMed Web of Science ®Google Scholar
• Cairo S, Wang Y, De Reyniès A, et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A. 2010;107(47):20471–20476.
   PubMed Web of Science ®Google Scholar
• Pu H, Zheng Q, Li H, et al. CUDR promotes liver cancer stem cell growth through upregulating TERT and C-Myc. Oncotarget. 2015;6(38):40775–40798.
   PubMedGoogle Scholar
• Cheng Z, Lei Z, Yang P, et al. Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway. Gene. 2019;684:95–103.
   PubMed Web of Science ®Google Scholar
• Liu HL, Tang HT, Yang HL, et al. Oct4 regulates the transition of cancer stem-like cells to tumor endothelial-like cells in human liver cancer. Front Cell Dev Biol. 2020;8:563316.
   PubMed Web of Science ®Google Scholar
• Zhu P, Wang Y, He L, et al. ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. J Clin Invest. 2015;125(10):3795–3808.
   PubMed Web of Science ®Google Scholar
• Li R, He Q, Han S, et al. MBD3 inhibits formation of liver cancer stem cells. Oncotarget. 2017;8(4):6067–6078.
   PubMedGoogle Scholar
• Liu L, Liu C, Zhang Q, et al. SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cells. Hepatology. 2016;64(3):814–827.
   PubMed Web of Science ®Google Scholar
• Sun D, Qin L, Xu Y, et al. Influence of adriamycin on changes in Nanog, Oct-4, Sox2, ARID1 and Wnt5b expression in liver cancer stem cells. World J Gastroenterol. 2014;20(22):6974–6980.
   PubMed Web of Science ®Google Scholar
• Karagonlar ZF, Akbari S, Karabicici M, et al. A novel function for KLF4 in modulating the de-differentiation of EpCAM-/CD133- nonStem cells into EpCAM+/CD133+ liver cancer stem cells in HCC cell line HuH7. Cells. 2020;9(5):1198.
   Web of Science ®Google Scholar
• Chen L, Shi J, Wu Y, et al. CircRNA CDR1as promotes hepatoblastoma proliferation and stemness by acting as a miR-7-5p sponge to upregulate KLF4 expression [published online ahead of print, 2020 Oct 14]. Aging (Albany NY). 2020;12(19):19233–19253.
   PubMedGoogle Scholar
• Castelli G, Pelosi E, Testa U. Liver cancer: molecular characterization, clonal evolution and cancer stem cells. Cancers (Basel). 2017;9(9):127.
   Web of Science ®Google Scholar
• Zheng H, Pomyen Y, Hernandez MO, et al. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology. 2018;68(1):127–140.
   PubMed Web of Science ®Google Scholar
• Yoshida GJ. The heterogeneity of cancer stem-like cells at the invasive front. Cancer Cell Int. 2017;17(1):23.
   PubMedGoogle Scholar
• Choe C, Kim H, Min S, et al. SOX2, a stemness gene, induces progression of NSCLC A549 cells toward anchorage-independent growth and chemoresistance to vinblastine. Onco Targets Ther. 2018;11:6197–6207.
   PubMed Web of Science ®Google Scholar
• Müller M, Hermann PC, Liebau S, et al. The role of pluripotency factors to drive stemness in gastrointestinal cancer. Stem Cell Res. 2016;16(2):349–357.
   PubMed Web of Science ®Google Scholar
• Yeo CD, Kang N, Choi SY, et al. The role of hypoxia on the acquisition of epithelial-mesenchymal transition and cancer stemness: a possible link to epigenetic regulation. Korean J Intern Med. 2017;32(4):589–599.
   PubMed Web of Science ®Google Scholar
• Qian J, Rankin EB. Hypoxia-induced phenotypes that mediate tumor heterogeneity. Adv Exp Med Biol. 2019;1136:43–55.
   PubMed Web of Science ®Google Scholar
• Reers S, Pfannerstill AC, Maushagen R, et al. Stem cell profiling in head and neck cancer reveals an Oct- 4expressing subpopulation with properties of chemoresistance. Oral Oncol. 2014;50(3):155–162.
   PubMed Web of Science ®Google Scholar
• Wang XQ, Ongkeko WM, Chen L, et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology. 2010;52(2):528–539.
   PubMed Web of Science ®Google Scholar
• Jia Q, Zhang X, Deng T, et al. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells. Cell Reprogram. 2013;15(2):143–150.
   PubMed Web of Science ®Google Scholar
• Jia X, Zhang Z, Luo K, et al. TCRP1 transcriptionally regulated by c-MYC confers cancer chemoresistance in tongue and lung cancer. Sci Rep. 2017;7(1):3744.
   PubMedGoogle Scholar
• Ganesan S. MYC. PARP1, and chemoresistance: BIN there, done that? Sci Signal. 2011;4(166):e15.
   Web of Science ®Google Scholar
• Yin X, Tang B, Li JH, et al. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway. J Exp Clin Cancer Res. 2017;36(1):166.
   PubMedGoogle Scholar
• Bai HY, Liao YJ, Cai MY, et al. Eukaryotic initiation factor 5A2 contributes to the maintenance of CD133(+) hepatocellular carcinoma cells via the c-Myc/microRNA-29b axis. Stem Cells. 2018;36(2):180–191.
   PubMed Web of Science ®Google Scholar
• Tripathi SC, Fahrmann JF, Celiktas M, et al. MCAM mediates chemoresistance in small-cell lung cancer via the PI3K/AKT/SOX2 signaling pathway. Cancer Res. 2017;77(16):4414–4425.
   PubMed Web of Science ®Google Scholar
• Zhi Y, Abudoureyimu M, Zhou H, et al. FOXM1-mediated LINC-ROR regulates the proliferation and sensitivity to sorafenib in hepatocellular carcinoma. Mol Ther Nucleic Acids. 2019;16:576–588.
   PubMedGoogle Scholar
• Méndez-Blanco C, Fondevila F, García-Palomo A, et al. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50(10):1–9.
   PubMedGoogle Scholar
• Jeon HM, Sohn YW, Oh SY, et al. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2 [published correction appears in Cancer Res. 2011 Jun 15;71(12):4325][published correction appears in Cancer Res. 2011 Sep 15;71(18):6085.Oh, Se-Young [corrected to Oh, Se-Yeong]]. Cancer Res. 2011;71(9):3410–3421.
   PubMed Web of Science ®Google Scholar
• Chou YT, Lee CC, Hsiao SH, et al. The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer. Stem Cells. 2013;31(12):2607–2619.
   PubMed Web of Science ®Google Scholar
• Fang T, Lv H, Wu F, et al. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation. Cancer Lett. 2017;384:50–59.
   PubMed Web of Science ®Google Scholar
• Murakami S, Ninomiya W, Sakamoto E, et al. SRY and OCT4 are required for the acquisition of cancer stem cell-like properties and are potential differentiation therapy targets. Stem Cells. 2015;33(9):2652–2663.
   PubMed Web of Science ®Google Scholar
• Wu DM, Zheng ZH, Zhang YB, et al. Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells. J Exp Clin Cancer Res. 2019;237:38.
   Google Scholar
• Lee SI, Kim DK, Seo EJ, et al. Role of krüppel-like factor 4 in the maintenance of chemoresistance of anaplastic thyroid cancer. Thyroid. 2017;27(11):1424–1432.
   PubMed Web of Science ®Google Scholar
• Hüser L, Novak D, Umansky V, et al. Targeting SOX2 in anticancer therapy. Expert Opin Ther Targets. 2018;22(12):983–991.
   PubMed Web of Science ®Google Scholar
• Deheeger M, Lesniak MS, Ahmed AU. Cellular plasticity regulated cancer stem cell niche: a possible new mechanism of chemoresistance. Cancer Cell Microenviron. 2014;1(5):e295.
   PubMedGoogle Scholar
• Cheng CC, Shi LH, Wang XJ, et al. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Int J Oncol. 2018;53(1):339–348.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang J, Yang X, et al. SALL4 as an epithelial-mesenchymal transition and drug resistance inducer through the regulation of c-Myc in endometrial cancer. PLoS One. 2015;10(9):e0138515.
   PubMed Web of Science ®Google Scholar
• Jang KY, Noh SJ, Lehwald N, et al. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One. 2012;7(9):e45119.
   PubMed Web of Science ®Google Scholar
• Zhang F, Li K, Yao X, et al. A miR-567-PIK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer. EBioMedicine. 2019;44:311–321.
   PubMed Web of Science ®Google Scholar
• Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer. 2006;6(1):11–23.
   PubMed Web of Science ®Google Scholar
• Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3(1):5.
   PubMedGoogle Scholar
• Li W, Zhou Y, Zhang X, et al. Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells. Sci Rep. 2017;7(1):46246.
   PubMedGoogle Scholar
• Abraham SA, Hopcroft LE, Carrick E, et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 2016;534(7607):341–346.
   PubMed Web of Science ®Google Scholar